BRCA2 mutations in primary breast and ovarian cancers

Abstract

The second hereditary breast cancer gene, BRCA2, was recently isolated1. Germline mutations of this gene predispose carriers to breast cancer, and, to a lesser extent, ovarian cancer. Loss of heterozygosity (LOH) at the BRCA2 locus has been observed in 30–40% of sporadic breast and ovarian tumours, implying thatBRCA2 may act as a tumour suppressor gene in a proportion of sporadic cases 2–5. To define the role of BRCA2 in sporadic breast and ovarian cancer, we screened the entire gene for mutations using a combination of techniques in 70 primary breast carcinomas and in 55 primary epithelial ovarian carcinomas. Our analysis revealed alterations in 2/70 breast tumours and none of the ovarian carcinomas. One alteration found in the breast cancers was a 2-basepair (bp) deletion (4710delAG) which was subsequently shown to be a germline mutation, the other was a somatic missense mutation (Asp3095Glu) of unknown significance. Our results suggest that BRCA2 is a very infrequent target for somatic inactivation in breast and ovarian carcinomas, similar to the results obtained torBRCAL

Access optionsAccess options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

References

  1. 1

    Wooster, R. et al. Identification of the breast cancer susceptibility gene BRCA2. Nature 378, 789–792 (1995).

  2. 2

    Lundberg, C. et al. Loss of heterozygosity in human ductal breast tumours indicates a recessive mutation on chromosome 13. Proc. Natl. Acad. Sci. USA 84, 2372–2376 (1987).

  3. 3

    Kim, T.M. et al. Loss of heterozygosity on chromosome 13 is common only in the biologically more aggressive subtypes of ovarian eptithelial tumors and is associated with normal retinoblastoma expression. Cancer Res. 54, 605–609 (1994).

  4. 4

    Collins, N. et al. Consistent loss of the wild type allele in breast cancers from a family linked to the BRCA2 gene chromosome 13q12–13. Oncogene 10, 1673–1675 (1995).

  5. 5

    Cleton-Jansen, A.M. et al.Loss of heterozygosity in sporadic breast tumors at the BRCA2 locus on chromosome 13q12–13. Br.J.Cancer 72, 1241–1244 (1995).

  6. 6

    Phelan, C.M. et al. Mutation analysis of the BRCA2 gene in 49 site-specific breast cancer families. Nature Genet. 13, 120–122 (1996).

  7. 7

    Futreal, P.A. et al. BRCA1 mutations in primary breast and ovarian carcinomas. Science 266, 120–122 (1994).

  8. 8

    Merajver, S.A. et al. Somatic mutations in the BRCA1 gene in sporadic ovarian tumours. Nature Genet. 9, 439–443 (1995).

  9. 9

    Hosking, L. et al. A somatic BRCA1 mutation in an ovarian tumour. Nature Genet. 9, 343–344 (1995).

  10. 10

    Takahashi, H. et al. Mutation analysis of the BRCA1 gene in ovarian cancers. Cancer Res. 55, 2998–3002 (1995).

  11. 11

    Kerangueven, F. et al. Patterns of loss of heterzygosity at loci from chromosome arm 13q suggest a possible involvement of BRCA2 in sporadic breast tumors. Genes Chrom. Cancer 13, 291–294 (1995).

  12. 12

    Chen, Y et al.Aberrant subcellular localization of BRCA1 in breast cancer. Science 270, 789–791 (1995).

  13. 13

    Thompson, M.E., Jensen, R.A., Obermiller, P.S., Page, D.L. & Holt, J.T. Decreased expression of BRCA1 accelerates growth and is often present during sporadic breast cancer progression. Nature Genet. 9, 444–450 (1995).

Download references

Author information

Correspondence to P. Andrew Futreal.

Rights and permissions

Reprints and Permissions

About this article

Further reading